Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Cholangiocarcinoma × futibatinib × Clear all

Phase

Phase 2/3 1 Phase 2 1

Status

Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasm Metastasis 1 Cholangiocarcinoma 1

Interventions

Gemcitabine 4 Cisplatin 4 pembrolizumab 2 Photochemotherapy 2 futibatinib 1 Taxes 1 Radiofrequency Ablation 1 Paclitaxel 1 Neoadjuvant Therapy 1 Lasers 1 Fulvestrant 1 Drug Therapy 1 Capecitabine 1 Albumin-Bound Paclitaxel 1 1-phenyl-3,3-dimethyltriazene 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06506955 2026-03-11

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

Taiho Oncology, Inc.

Phase 2/3 Enrolling by invitation

Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡